Dr Mark Treherne
Prior to this, Mark has carried out research work with Pfizer and in 1997 set up Cambridge Drug Discovery (CDD) as Chief Executive which was sold to BioFocus in 2001.
Mark was formerly Chairman of ERBI for 3 years, which represents the biotechnology companies in the East of England (now One Nucleus). He was also Chief Executive of the Life Sciences Organisation of UK Trade & Investment until 2016. Mark is an author of over 70 articles published in the scientific and trade press.
Andrew Hopkinson, PhD, is the Chief Executive Officer, founder and visionary of NuVision. Andrew has 15 years’ translational research expertise in ophthalmic regenerative medicine as the Principal Research Fellow at Nottingham Centre For Eye research, which is part of Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham.
During his time at the University he and his multidisciplinary research team have been engaged in developing innovative technologies to repair and regenerate the injured ocular surface for visual rehabilitation. His research pioneered the development of Tereo processing and Omnigen. He continues to drive ground breaking research discoveries from the bench to pre-clinical and clinical realisation, to create an exciting future portfolio of innovative Biotherapies for NuVision.
During his academic career, Dr Hopkinson has published over 50 scientific papers in leading journals in the fields of ophthalmology and tissue engineering, and has filed 4 patents.
Dr Andrew Hopkinson
Chief Scientific Officer
Independent Non-Executive Director
Roger Teasdale joined the Board as an Independent Non-Executive Director in 2018. Roger enjoyed a successful 25 year career at Smith & Nephew, the FTSE 100 Medical device business focused on the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of $4.8bn and operations in 120 countries. For his last 5 years at Smith & Nephew, Roger was President of the Global Advanced Wound Management business with sales of $1.4bn and 4000 people in 80 countries. Roger gained a proven international track record in driving revenue and profit growth in the medical device industry. His most recent role is Group Managing Director at Premier Technical Services Group, a listed niche specialist service provider. Roger is a qualified Chartered Accountant and holds a BA in Accounting and Management Control.
Adrian Del Arenal Martin is a Biotechnology Engineer from the Monterrey Institute of Technology in Mexico. He has pilot plant lab experience with recombinant protein bioprocessing. He also graduated from the University of Nottingham with a MSc. in Biopharmaceutics and Business and has gained start-up business knowledge as a intern SME consultant at BioCity.
Adrian joined the team in 2017 as a Intern Manufacturing Technician, and since summer 2018, he has been appointed as the Operations Manager for the company. He is now the responsible for overseeing procurement, human resources, sales order processing and other general operations areas
Adrian Del Arenal
María J. Mendoza is the Quality Manager at NuVision. Her experience includes molecular, cell biology and immunology research. Graduated from the University of Nottingham with a MSc. in Stem Cell Technology, she has knowledge of regenerative therapies and translational technologies. As an intern in NuVision, Maria has been involved in the translation and implementation of Omnigen manufacture into clinical standards. Then she became production manager overseeing Omnigen manufacture, process development and translation of new research technologies into clinical standards following the HTA requirements.
Geert holds a Master’s Degree in Biological Science from the University of South Africa, a Bachelor’s degree in Veterinary Reproductive Sciences and Molecular Biology from the Tshwane University of Technology and a Diploma in Tissue Banking from the Universitat De Barcelona. He is experienced in ISO 9001 and ISO 13485 Quality Management Systems.
Designated Individual and Regulatory Manager
Medical Science Liaison
Tonicha Spencer is the Medical Science Liaison at NuVision. Following an internship, Tonicha joined NuVision in 2018 after completing a Master’s degree in Medicinal Chemistry from the University of Leeds. Tonicha is involved in aiding clinical research regarding Omnigen for application in ophthalmology.
Emily has a dual role also working as a post-doctoral research associate in Academic Ophthalmology at the University of Nottingham. Her research interests focus on the development of Omnigen application for acute ocular surface trauma.
Dr Emily Britchford
Research and Development Officer
Duncan Rawlins & Joe Brown
Interested in purchasing Omnigen?
Register your interest
Have a question about our products or pipelines?
Speak to our team of experts